Danaher Corporation vs NetFlix Inc — how do they compare? Danaher Corporation trades at $207.45 (market cap $145.83B), while NetFlix Inc trades at $75.06 (market cap $311.42B). The key difference: NetFlix Inc is far larger — about 2.1× Danaher Corporation's market cap, and Danaher Corporation pays a 0.77% dividend while NetFlix Inc pays none. Which is the better fit depends on your goals.
| DHR | NFLX | |
|---|---|---|
Market Cap | $145.83B | $311.42B |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $126.33 |
52-Week Low | $161.91 | $67.60 |
Enterprise Value | $168.04B | $316.60B |
Dividend Yield | 0.77% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Netflix (NFLX) trades at $76.29, up 2.9% in the last session, showing resilience amid recent volatility. The stock exhibits bullish technical signals with strong moving average alignment, though RSI levels suggest potential overbought conditions near-term. Fundamentally, Netflix demonstrates robust growth with Q1 2026 EPS beating expectations at $1.23 versus $0.763, and revenue climbing to $45.18 billion in 2025. Operating cash flow surged to $10.15 billion, underscoring financial health. The company's expansion into advertising and live sports is viewed positively by analysts.
Outlook remains favorable with a consensus price target of $90.45, implying ~19% upside, supported by 64% analyst buy ratings. Key opportunities include ad-tier monetization and global content leadership. Risks involve competitive pressures from streaming rivals, execution on new initiatives, and market sentiment shifts. The stock's current valuation at P/E 23.52 appears reasonable given earnings growth trajectory, but investors should monitor quarterly execution against high expectations.
Trailing returns across standard periods
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →